NEULANDLAB2020-10-012020-12-31in-bse-fin:OneOperatingExpenses01Member NEULANDLAB2020-10-012020-12-31in-bse-fin:OneOperatingExpenses02Member NEULANDLAB2020-10-012020-12-31in-bse-fin:FourOperatingExpenses01Member NEULANDLAB2020-10-012020-12-31in-bse-fin:FourOperatingExpenses02Member NEULANDLAB2020-10-012020-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member NEULANDLAB2020-10-012020-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member NEULANDLAB2020-10-012020-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member NEULANDLAB2020-10-012020-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member NEULANDLAB2020-10-012020-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member NEULANDLAB2020-10-012020-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares NEULANDLAB 2020-04-01 2021-03-31 2021-01-07 INR Lakhs Third quarter Single segment Manufacturing of Active Pharmaceutical Ingredients 2020-10-01 2020-12-31 Unaudited Consolidated 2453918000.00 1953000.00 2455871000.00 1100930000.00 0.00 21268000.00 379019000.00 44393000.00 104084000.00 486700000.00 2136394000.00 319477000.00 0.00 319477000.00 43291000.00 8834000.00 52125000.00 0.00 267352000.00 0.00 0.00 0.00 0.00 267352000.00 1257000.00 268609000.00 0.00 0.00 0.00 0.00 129005000.00 10 20.84 20.84 0.00 0.00 20.84 20.84 1. The financial results for the quarter and nine months ended 31 December 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 2 February 2021. n n2. The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. n n3. The Consolidated Financial Results include results of the following wholly owned subsidiaries: n(a) Neuland Laboratories Inc., USA n(b) Neuland Laboratories KK., Japan. n n4. The operations of the Company and its subsidiaries are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 Operating Segments . n n5. The Group continues to evaluate the impact of the pandemic on all aspects of its business, including impact on customers, employees, vendors and business partners. The Group has taken several business continuity measures including transport for factory employees, work from home, following the social distancing norms.The Group has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, inventory, based on the information available to date, both internal and external, while preparing the its financial results for the quarter ended 31 December 2020. Based on the assessment done by the management, there is no significant/material impact of COVID-19 on the results for the quarter ended 31 December 2020. The Group has been closely monitoring any material changes to future economic conditions. n n6. The EPS for quarters has not been annualised. n n7. The previous period figures have been regrouped/rearranged wherever necessary to make it comparable with the current period. Single segment 2020-04-01 2020-12-31 Unaudited Consolidated 6922084000.00 14986000.00 6937070000.00 3204707000.00 0.00 91578000.00 1063126000.00 133204000.00 285405000.00 1349616000.00 6127636000.00 809434000.00 0.00 809434000.00 78083000.00 97970000.00 176053000.00 0.00 633381000.00 0.00 0.00 0.00 0.00 633381000.00 -814000.00 632567000.00 0.00 0.00 0.00 0.00 129005000.00 10 49.37 49.37 0.00 0.00 49.37 49.37 Manufacturing expenses 304371000.00 Other expenses 182329000.00 Manufacturing expenses 854955000.00 Other expenses 494661000.00